Biotron (ASX:BIT) has announced it will present the latest data on BIT225 HIV-1 at the 23rd International AIDS Conference (AIDS 2020: Virtual) in July.
The conference will bring together leading researchers from around the world to share the latest studies and developments in the ongoing battle against HIV/AIDS and other global infectious diseases including COVID-19.
The company said that, since completing the BIT225-009 phase two HIV-1 clinical trial and releasing positive results in late 2018, it has continued to characterise the unique mechanism of action of its lead anti-HIV-1 drug, BIT225.
It said the phase two trial and subsequent post-trial analyses demonstrated BIT225 induces significant beneficial immunological changes. These may lead to boosting the body’s immune system and eliminating virus reservoirs that persist despite treatment with conventional anti-HIV-1 drugs.
Biotron said its latest data to be presented at AIDS 2020: Virtual builds on previously reported studies of the mechanism of action of BIT225. The paper was accepted as a late-breaker abstract for inclusion in the conference program.
The company said it is currently working with international HIV-1 experts to map out the next stage of development of BIT225.
It added that chronic toxicology studies of BIT225 undertaken by a contract research organisation have been completed.
"These six-month preclinical studies are important as they enable long-term dosing of BIT225 in future clinical studies in HIV-1 infected patients," it said.